• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Drug-induced liver injury (DILI) in vitro services

A sensitive and specific means to predict hepatotoxicity


Employing our Liver-on-a-chip hepatic co-culture model (evaluated by our collaborators at the U.S. FDA), our DILI in vitro Service can screen your small molecules, antibodies, ASO, and gene editing reagents to establish human DILI risk.

Alternatively, use our Service to perform comparative cross-species (human, rat and dog) Liver-on-a-chip studies. De-risk development and minimize animal testing by flagging interspecies differences early, or use the Service to provide clarity regarding which in vivo species is more human predictive when uncertainties arise.

Watch this short video to learn more

DILI animal CRS video

Service overview:

Our Service assesses at least six hepatic health parameters simultaneously, including clinical markers of liver injury. This approach achieves the sensitivity and specificity required to identify hepatotoxins missed in animals, and other in vitro assays.

  • Test a range of drugs to enable lead or candidate selection
  • Derive cross-species data to better inform animal studies, or explain non-concordant findings
  • Explore DILI under a range of conditions: healthy, inflammation, steatotic
  • Test highly human-specific new modalities
  • Compare acute vs chronic toxicity responses
  • Investigate drug–drug interaction events
  • Check for CYP induction or inhibition
  • Use retained samples to understand drug metabolism
  • Bespoke human multi-organ, or studies with circulating human immune cells available on request

Customer feedback

I worked with CN Bio on a DILI Services project to predict which formulation of the same test agent would be safe for humans. Previous In vivo studies demonstrated inter-species differences between the formulations in animals but thanks to the expertise of CN Bio, I was able to rapidly gain human-relevant data that helped to move my project forward.

Professor Gerry Boss M.D.

Distinguished Professor of Medicine, Department of Medicine. UCSD

View more PhysioMimix reviews on SelectScience

Professor Gerry Boss M.D. photo

Why choose this DILI in vitro Service?

cnb icons cal ticks | In vitro hepatotoxicity services

Early insights

Flag interspecies differences early to better inform in vivo study design

icon protection | In vitro hepatotoxicity services

Protect study validity

Mitigate the risk of late-stage conflicting data, or drug misclassification

icon dog 1 | In vitro hepatotoxicity services

Reduce animal use

Safeguard and reduce unnecessary in vivo animal use

icon adme | In vitro hepatotoxicity services

Address the cause​

Identify the mechanism of human DILI to address the cause​

icon data report | In vitro hepatotoxicity services

Mitigate risk

Mitigate the risk of late-stage conflicting data, or drug misclassification

How the service works:

Through the co-culture of primary human hepatocytes and non-parenchymal cells, and the evaluation of multiple endpoints, our assay offers a complete assessment of DILI risk.

Couple with comparative rat (Sprague-Dawley) and/ or dog (Beagle) primary hepatocyte assays for cross-species insights.

Our service provides higher content data than spheroids and sufficient throughput to deliver concentration-response curves.

Your dedicated contact will work collaboratively with you from the start to the end of the project.

  1. Design and finalize experiment plan
  2. Customer supplies required amount of drug(s)
  3. Two weeks to complete cell culture
  4. Two weeks to run endpoint assays, analyze data and complete the report
  5. One to two months to complete the study from receiving an order

Standard DILI cell culture timeline

a Standard DILI cell culture timeline
DILI assays can be extended to 14 days upon request

Endpoint measurements

milti chip plates | In vitro hepatotoxicity services

Included, but are not limited to:

Functionality biomarkers

  • Cytochrome P450 enzyme activity
  • Albumin production
  • Urea production

Clinical liver heath biomarkers

  • Lactose dehydrogenase (LDH) release
  • Adenosine Triphosphate (ATP)
  • Aspartate Transferase (AST)/Alanine amino transferase (ALT)

Optional profiling analysis

  • Quantitative PCR
  • Transcriptomics

Related applications

DILI

Drug-induced liver injury

Our human DILI assay can assess the toxicity of a wide range of entities (small molecules, protein, ASOs, AAVs, etc) in the presence or absence of liver disease.

Human and cross-species DILI assays facilitate more informed predictions of inter-species differences in response to acute, or repeated drug exposure via in vivo translatable endpoints.

Learn more
LC12 plate close up

News

nc3rs | In vitro hepatotoxicity services

3Rs project with FDA

CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI

Learn more

Learn more about our DILI Services

Request more info

Featured resources

Scientific publications

Characterizing Repreducibility MPS 2020 Graphic | In vitro hepatotoxicity services

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation

Scientific publications

Human Liver Microphysiological System for Assessing Drug Induced Liver Toxicity In Vitro | In vitro hepatotoxicity services

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Webinars

web s4e3 | In vitro hepatotoxicity services

Fighting Toxic Chemicals: Evaluating the Safety of Cobinamide as a Neutralizing Agent

News & Blogs

blog lung in crisis | In vitro hepatotoxicity services

Understanding the mechanism of toxicity: OOC’s crucial role

Brochures & Flyers

A4 resource mockup Template | In vitro hepatotoxicity services

Organ-on-a-chip Contract Research Services Brochure

View all Drug-induced liver injury Service related resources

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo